Compare Cassava Sciences Inc (FLNA) vs Southern Copper Corp (SCCO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs Southern Copper Corp — how do they compare? Cassava Sciences Inc trades at $1.07 (market cap $53.14M), while Southern Copper Corp trades at $179.5 (market cap $151.46B). The key difference: Southern Copper Corp is far larger — about 2850.2× Cassava Sciences Inc's market cap, and Southern Copper Corp pays a 2.2% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals.
| FLNA | SCCO | |
|---|---|---|
Market Cap | $53.14M | $151.46B |
Sector | Health | Basic Materials |
52-Week High | $4.64 | $218.85 |
52-Week Low | $1.09 | $90.54 |
Enterprise Value | -$33.43M | $153.52B |
Dividend Yield | — | 2.2% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Filana Therapeutics (FLNA) trades at $1.09, down 5.22% on the day, reflecting persistent operational losses despite recent earnings beats. The stock exhibits a strong bearish technical signal, with moving averages and oscillators aligned negatively. Fundamentally, the company is in a pre-revenue biotech development phase, evidenced by significant negative cash flow from operations (-$32.25M in 2025) and deeply negative profitability metrics (ROE: -79.59%). Recent news highlights continued focus on its Tuberous Sclerosis Complex (TSC)-related epilepsy program.
The outlook is bifurcated: a bullish analyst consensus (8 Buy, 4 Hold, 0 Sell) suggests optimism for the clinical pipeline, while severe financial burn and bearish technicals present substantial near-term risk. Investment opportunity hinges entirely on successful drug development, with significant dilution or financing risk as the company funds operations. The stock is suitable only for high-risk investors comfortable with binary clinical outcomes.
Southern Copper (SCCO) trades at $182.38, up 4.5% on the day, with a bullish technical signal and strong earnings momentum, having beaten EPS estimates for three consecutive quarters. The company demonstrates robust fundamentals with revenue growth from $10.0B in 2022 to $13.4B in 2025 and a net income margin of 34.13%. Recent positive news highlights its role in the AI-driven copper demand narrative.
Outlook is supported by strong profitability and growth trends, but risks include high valuation multiples and a mixed analyst consensus. The stock trades above the consensus price target of $151.58, indicating potential overvaluation concerns amidst bullish technicals and fundamental strength.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About Southern Copper Corp
Southern Copper Corp is an integrated producer of copper and other minerals and operates the mining, smelting, and refining facilities in Peru and Mexico. Its production includes copper, molybdenum, zinc, and silver. The company operates through the following segments: Peruvian operations, Mexican open-pit operations, and Mexican underground mining operations. Southern Copper generates the majority of its revenue from the sale of copper and the rest from the sale of non-copper products, such as molybdenum, silver, zinc, lead, and gold. Its geographical segments are The Americas, Europe, and Asia.
Read more on SCCO →
